Multimeric Biotherapeutics, Inc.

UEI
MJFMX1Q4KGE7
CAGE
5CZ90
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Ebov GP vaccine production W81XWH17C0239 Medical Command (Army) $0

Grant awards

Award Agency Obligated Awarded
Magavax vaccine for ebola R43CK000494 Centers for Disease Control and Prevention $225,000
Magavax therapeutic vaccine for chronic HBV infection R43DK108606 National Institutes of Health $223,899
Ovarian cancer therapy using CD40 ligand (CD40L) R43CA180323 National Institutes of Health $223,157
Development of a multimeric CD40 ligand vaccine adjuvant R43AI098246 National Institutes of Health $593,401
Precision immunization vaccine for nicotine and other drugs of abuse R21DA029435 National Institutes of Health $344,750

Quick answers

Is Multimeric Biotherapeutics, Inc. registered in SAM.gov?

Multimeric Biotherapeutics, Inc.'s SAM.gov registration expired on November 19, 2021.

What is Multimeric Biotherapeutics, Inc.'s most recent federal award?

Multimeric Biotherapeutics, Inc.'s most recent federal contract award is Ebov GP vaccine production (W81XWH17C0239), from Medical Command (Army), on September 25, 2017.

On GovTribe

See Multimeric Biotherapeutics, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login